Author Archives: Clark Herman

Orphan Drug Adoption: the More Regulation, the Better

New survey research indicates that a country with a strong regulatory commitment for advancing drugs for rare diseases does better in getting orphan drugs to patients than countries with lesser regulatory frameworks. In his study, ‘The Effect of Market-Based Economic Factors on the Adoption of Orphan Drugs Across Multiple Countries,’ John Matthews, Associate Director of […]
Posted in Europe, Global, Market Access, Orphan Drugs, pricing, Regulatory | Tagged , , , , , , | Leave a comment

Why the Slow Take-up of Comparative Effectiveness Research? It's Time and Money, Says a New PCORI Survey

Earlier this week, the federal government’s Patient Centered Outcomes Research Institute (PCORI) unveiled a new survey, revealing that both patients and clinicians want in health research to focus on one thing: improving outcomes. A panel of healthcare providers discussed how findings will impact the structure and content of comparative effectiveness research (CER), advocating patient-centric dissemination […]
Posted in healthcare, Medical Education, Meetings, multimedia, Patient Communication, patient education, Strategy, Technology | Tagged , , , , , , , , | Leave a comment

Filling the Rx Gap: Cost Solutions at the Point-of-Sale

Prescription abandonment—cited as one of the major cost-related issues in healthcare—has prompted numerous efforts to raise the profile of pharmacists in driving improvements in patient utilization. With a marked decline in engagement elsewhere—physician prescribers are seeing fewer sales reps and DTC spending is ebbing – more solutions providers are seeking to fill the gap, with […]
Posted in Strategy | Tagged , , , , , , , , , , , | 3 Comments

FDA’s New Breakthrough Designation Process: A Patient Perspective

With the FDA holding its first patient-focused drug development meeting in October of last year, regulators are starting to take notice of the impact disease-based organizations can have in improving drug trial design for new therapies—particularly for rare diseases. According to Teresa Barnes, Vice President of Patient Outreach & Program Support for the Coalition for […]
Posted in FDA, Orphan Drugs, People, R&D, Regulatory, Strategy | Tagged , , , , , , , , , , , , , , , , , | Leave a comment

For What it’s Worth: Study Probes Evolving Value Schemes

PharmaFutures’ Pathways to Value: Pharma in a Changing World explains how the industry may move forward to combine business imperatives and social mandates through new strategies for determining value and reimbursement for medicines. The study determines that collaboration across three fronts is needed to ensure that value is recognized and adapted over time, taking into […]
Posted in Emerging Markets, Europe, Market Access, pricing, R&D, Regulatory, Strategy | Tagged , , , , , , , | Leave a comment
  • Categories

  • Meta